๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Folate-mediated targeting: from diagnostics to drug and gene delivery

โœ Scribed by Christopher P. Leamon; Philip S. Low

Book ID
114383332
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
624 KB
Volume
6
Category
Article
ISSN
1359-6446

No coin nor oath required. For personal study only.

โœฆ Synopsis

The covalent attachment of the vitamin folic acid to almost any molecule yields a conjugate that can be endocytosed into folate receptor-bearing cells. Because folate receptors are significantly overexpressed in the majority of human cancers, this methodology is currently being investigated for the selective delivery of imaging and therapeutic agents to tumor tissue. Phase I and II clinical studies for the first folate-containing imaging agent were initiated in 1999, and clinical trials of folate-targeted therapeutic agents should soon follow. This review will summarize folate-mediated drug delivery and highlight those techniques undergoing active preclinical or clinical investigation.

๐Ÿ“œ SIMILAR VOLUMES

Folate receptor-mediated drug targeting:
Folate receptor-mediated drug targeting: From therapeutics to diagnostics
โœ Andrew R. Hilgenbrink; Philip S. Low ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 185 KB

Folate targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of many cancers and inflammatory diseases. Due to its small molecular size and high binding affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety of mo

The use of nanoparticle-mediated targete
The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance
โœ Yogesh B. Patil; Suresh K. Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panya ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 805 KB

Overexpression of drug efflux transporters such as P-glycoprotein (P-gp) enables cancer cells to develop resistance to multiple anticancer drugs. Functional inhibitors of P-gp have shown promising efficacy in early clinical trials, but their long-term safety is yet to be established. A novel approac